Abstract
Contraceptive vaginal rings (CVR) offer the benefit of safe, effective, and patient-controlled reversible contraception without the need for daily dosing. There are currently two CVRs in commercial use worldwide, including the etonogestrel/ethinyl estradiol (ENG/EE) CVR and a progesterone-only ring approved in some countries for postpartum lactating women. This chapter focuses on the ENG/EE CVR (NuvaRing®) approved by the US FDA. Pharmacokinetics, mechanism of action, effectiveness, advantages and disadvantages, and counseling tips are addressed. Additionally, this chapter includes a discussion of drug interactions and side effects, including the risk of venous and arterial thromboembolism with vaginal as compared to oral ethinyl estradiol.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bahamondes L, Bahamondes MV. New and emerging contraceptives: a state-of-the-art review. Int J Womens Health. 2014;4(6):221–34.
Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception. 2013;87(3):314–8.
Brache V, Sitruk-Ware R, Williams A, Blithe D, Croxatto H, Kumar N, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception. 2012;85(5):480–8.
Mohamed AMM, El-Sherbiny WSM, Mostafa WAI. Combined contraceptive ring versus combined oral contraceptive (30 mcg ethinylestradiol and 3-mg drospirenone). Int J Gynecol Obstet. 2011;114(2):145–8.
Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception. 2008;78(1):4–9.
Timmer C, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39(3):233–42.
van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74.
Bruni V, Pontello V, Luisi S, Petraglia F. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing®. Eur J Obstet Gynecol Reprod Biol. 2008;139(1):65–71.
Mulders TM, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75(5):865–70.
Dragoman M, Petrie K, Torgal A, Thomas T, Cremers S, Westhoff CL. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception. 2013;87(4):432–6.
Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
Mulders TMT, Dieben TOM, Coelingh Bennick H. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod. 2002;17(10):2594–9.
Hatcher R, Trussell J, Nelson AL, Cates W. Contraceptive technology. 20th ed. Tiger, GA: Bridging the Gap Foundation; 2011.
Durand M, Seppala M, Cravioto MDC, Koistinen H, Koistinen R, González-Macedo J, et al. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception. 2005;71(6):451–7.
Winner B, Peipert JF, Zhao Q, Buckel C, Madden TE, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.
Dieben T, Roumen F, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100(3):585–93.
Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CHJ, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005;71(3):176–82.
Westhoff C. Higher body weight does not affect NuvaRing’s efficacy (abstract). Obstet Gynecol. 2005;105(4S):56S.
McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol. 2013;121(3):585–92.
Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.
Gilliam ML, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey EM. Adherence and acceptability of the contraceptive ring compared with the pill among students. Obstet Gynecol. 2010;115(3):503–10.
Stewart FH, Brown BA, Raine TR, Weitz TA, Harper CC. Adolescent and young women’s experience with the vaginal ring and oral contraceptive pills. J Pediatr Adolesc Gynecol. 2007;20(6):345–51.
Ballagh S, Babb T, Kovalevsky G, Archer DF. Contraceptive ring compliance: as labeled versus calendar based use. Fertil Steril. 2003;80(3):S54.
Creinin MD, Meyn L, Borgatta L, Barnhart KT, Jensen JT, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch. Obstet Gynecol. 2008;111(2):267–77.
Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 2002;186(3):389–95.
Oddsson K. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 g ethinylestradiol and 150 g levonorgestrel: a randomized trial. Hum Reprod. 2004;20(2):557–62.
Miller L, Verhoeven CHJ, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol. 2005;106(3):473–82.
Guazzelli CAF, Barreiros FA, Barbosa R, de Araújo FF, Moron AF. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception. 2009;80(5):430–5.
Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004;104(3):555–63.
Rad M, Kluft C, Menard J, Burggraaf J, de Kam ML, Meijer P, et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol. 2006;195(1):72–7.
Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008;78:1–8.
Magnusdóttir EM, Bjarnadóttir RI, Önundarson PT, Gudmundsdóttir BR, Geirsson RT, Magnusdóttir SD, et al. The contraceptive vaginal ring (NuvaRing®) and hemostasis: a comparative study. Contraception. 2004;69(6):461–7.
Grimes DA, Schulz KF, Raymond E. Surrogate end points in women’s health research: science, protoscience, and pseudoscience. Fertil Steril. 2010;93(6):1731–4.
Ouellet-Hellstrom R, Graham DJ. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. FDA Office of Surveillance and Epidemiology. 2011;1–57.
Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93–100.
Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ. 2012;344:e2990.
Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800–8.
Abdul Sultan A, Tata LJ, Grainge MJ, West J. The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis. PLoS One. 2013;8(7):e70310.
Meng K, Hu X, Peng X, Zhang Z. Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2015;28:1–9.
Virkus R, Lokkegaard E, Lindegaard O, Langhoff-Roos J, Nielson A, Rothman K, et al. Risk factors for venous thromboembolism in 1.3 million pregnancies: a nationwide prospective cohort. PLoS One. 2014;9(5):e96495.
Pomp E, Lenselink A, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632–7.
Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2000;5(4):265–74.
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–5.
Lidegaard O, Lokkegaard E, Jensen A, Skovlund C, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257–66.
Gallo MF, Lopez LM, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight (Review). Cochrane Database Syst Rev. 2012;1–116.
O’Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception. 2005;72(5):323–7.
Tuppurainen M, Klimscheffskij R, Venhola M, Dieben TOM. The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: a comparative study. Contraception. 2004;69(5):389–94.
Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception. 2007;76(5):348–56.
Barnhart KT, Schreiber C. Return to fertility following discontinuation of oral contraceptives. Fertil Steril. 2009;91(3):659–63.
Raman-Wilms L, Tseng A, Wighardt S, Einarson T, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1995;85(1):1–9.
Nelson HD, Zakher B, Cantor A, Fu R, Griffin J. Risk factors for breast cancer for women age 40–49: systematic review and meta analysis. Ann Intern Med. 2013;156(9):635–48.
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling J, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–32.
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–98.
Milne RL, Knight JA, Esther JM. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350–6.
Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091–1.
Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–50.
Center for Disease Control. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Morb Mortal Wkly Rep. 2010;59:1–88.
Verhoeven CHJ, van den Heuvel MW, Mulders TMT, Dieben TOM. The contraceptive vaginal ring, NuvaRing®, and antimycotic co-medication. Contraception. 2004;69(2):129–32.
Verhoeven CHJ, Dieben TOM. The combined contraceptive vaginal ring, NuvaRing®, and tampon co-usage. Contraception. 2004;69(3):197–9.
Haring T, Mulders TMT. The combined contraceptive ring NuvaRing® and spermicide co-medication. Contraception. 2003;67(4):271–2.
Christensen J, Petrenaite V, Atterman J, Sidenius P, Öhman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48(3):484–9.
Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Physical examination prior to initiating hormonal contraception: a systematic review. Contraception. 2013;87(5):650–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Simmons, K.B., Jensen, J.T. (2016). Contraceptive Ring. In: Shoupe, D., Mishell, Jr., D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana Press, Cham. https://doi.org/10.1007/978-3-319-20185-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-20185-6_7
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-20184-9
Online ISBN: 978-3-319-20185-6
eBook Packages: MedicineMedicine (R0)